Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals's GHG Emissions Data Preview
In 2025, Glenmark Pharmaceuticals completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Glenmark Pharmaceuticals has also provided a category-level breakdown for 8 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2025 | 2024 | 2023 | 2022 - 2017 |
|---|---|---|---|---|
Total Scope 1 | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  b | 0000000 |
Total Scope 2 | ||||
Market-Based | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Location-Based | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Unspecified Calculation Method | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data.  b | 0000000 |
Total Scope 3 | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  b | 0000000 |
Total Scope 1 Revenue Intensity (tCO2e/$M) | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  b | 0000000 |
a
b
a
b
a
b
a
b
a
b
a
b
a
b
a
bVerified Sources Behind Glenmark Pharmaceuticals’s Greenhouse Gas (GHG) Emissions Data
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Glenmark Pharmaceuticals’s data sources below and access millions more through our Disclosure Search.
Insights into Glenmark Pharmaceuticals's Operational Emissions
In 2025, the total operational greenhouse gas (GHG) emissions of Glenmark Pharmaceuticals amounted to 187,292 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2). a
Compared to 2024, the total operational greenhouse gas (GHG) emissions of Glenmark Pharmaceuticals increased by 120.7%, suggesting that the company faced challenges in reducing its emissions from its core operations. a
Glenmark Pharmaceuticals's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are Glenmark Pharmaceuticals's Scope 1 emissions?
In 2025, the total Scope 1 emissions of Glenmark Pharmaceuticals were 34,547 metric tons of CO₂ equivalent (tCO₂e). a
Has Glenmark Pharmaceuticals reduced its Scope 1 emissions over time?
Since 2021, Glenmark Pharmaceuticals's Scope 1 emissions have increased by 194.95%, reflecting a rising long-term trend in Scope 1 emissions over time. a b
Compared to the previous year (2024), Glenmark Pharmaceuticals's Scope 1 emissions increased by 126.69%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations. a
What are Glenmark Pharmaceuticals's Scope 2 emissions?
In 2025, Glenmark Pharmaceuticals reported Scope 2 greenhouse gas (GHG) emissions of 152,745 tCO₂e using the market-based method. a
Has Glenmark Pharmaceuticals reduced its Scope 2 emissions over time?
Compared to the previous year (2024), Glenmark Pharmaceuticals's Scope 2 emissions (Market-Based) rose by 119.39% in 2025, suggesting that the company faced challenges in reducing emissions from purchased electricity and energy a
What methodology does Glenmark Pharmaceuticals use for Scope 2 reporting?
In 2025, Glenmark Pharmaceuticals reported its Scope 2 emissions using the market-based method. a
Glenmark Pharmaceuticals's Scope 2 Emissions Over Time
- Total Scope 2 Market-Based
- Total Scope 2 (Unspecified Calculation Method)
Insights into Glenmark Pharmaceuticals's Value Chain Emissions
In 2025, Glenmark Pharmaceuticals reported 313,418 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain. a
The 2025 disclosure of Glenmark Pharmaceuticals includes a breakdown across 8 of the 15 Scope 3 categories defined by the GHG Protocol, up from 0 in 2024, reflecting improved emissions accounting practices and greater transparency across the company's value chain a
Glenmark Pharmaceuticals's Scope 3 Emissions Over Time
- Total Scope 3
- Year-over-Year Change
What are Glenmark Pharmaceuticals's Scope 3 emissions?
In 2025, Glenmark Pharmaceuticals reported total Scope 3 emissions of 313,418 metric tons of CO₂ equivalent (tCO₂e). a
Approximately 100% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0% came from downstream activities like product use, distribution, and end-of-life treatment. a
Has Glenmark Pharmaceuticals reduced its Scope 3 emissions over time?
Since 2021, Glenmark Pharmaceuticals's Scope 3 emissions have increased by 77.52%, reflecting a rising long-term trend in Scope 3 emissions over time. a b
Compared to the previous year (2024), Glenmark Pharmaceuticals's Scope 3 emissions increased by 83.32%, suggesting that the company faced challenges in reducing emissions across its value chain. a
What categories of Scope 3 emissions does Glenmark Pharmaceuticals disclose?
In 2025, Glenmark Pharmaceuticals reported emissions for 8 out of the 15 Scope 3 categories defined by the GHG Protocol. a
This partial disclosure allows for some insight into the company's indirect impacts.
What are the main sources of Glenmark Pharmaceuticals's Scope 3 emissions?
In 2025, the largest contributors to Glenmark Pharmaceuticals's Scope 3 emissions were: a
- Purchased Goods and Services (Cat. 1): 44,876 tCO₂e (28.62%)
- Downstream Transportation and Distribution (Cat. 9): 44,668 tCO₂e (28.49%)
- Upstream Transportation and Distribution (Cat. 4): 27,500 tCO₂e (17.54%)
Glenmark Pharmaceuticals's Scope 3 Emissions by Categories
Insights into Glenmark Pharmaceuticals’s GHG Emissions Intensity Compared to Industry Peers
In 2025, Glenmark Pharmaceuticals reported Scope 1 greenhouse gas (GHG) emissions of 34,547 tCO₂e and total revenues of USD 1,539 millions. This translates into an emissions intensity of 22.45 tCO₂e per millions USD. a
Glenmark Pharmaceuticals's Scope 1 Emissions Intensity Compared to Peers
How does Glenmark Pharmaceuticals's GHG emissions intensity compare to its peers?
In 2025, Glenmark Pharmaceuticals reported a Scope 1 emissions intensity of 22.45 tCO₂e per millions USD. Compared to the peer group median of 28.64 , this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors. a
Where does Glenmark Pharmaceuticals rank on GHG emissions intensity within its industry?
In 2025, Glenmark Pharmaceuticals ranked 12 out of 24 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD). a
Glenmark Pharmaceuticals is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency. a
Insights into Glenmark Pharmaceuticals's Total Carbon Footprint
In 2025, Glenmark Pharmaceuticals reported a total carbon footprint of 500,710 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 95.72% increase compared to 2024, suggesting a rise in emissions across its operations or value chain. a
The largest contributor to Glenmark Pharmaceuticals's total carbon footprint was Scope 3 emissions, accounting for 62.59% of the company's total carbon footprint, followed by Scope 2 emissions at 30.51%. a